CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biomx Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biomx Inc
22 Einstein St., Floor 4
Phone: +972 723942377p:+972 723942377 NESS-ZIONA, 7414003  Israel Ticker: PHGEPHGE
Business Summary
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Russell G.Greig 70 10/1/2019 10/1/2019
Chief Executive Officer, Director Jonathan E.Solomon 46 10/1/2019 10/1/2019
Chief Financial Officer MarinaWolfson 39 4/1/2022 12/1/2019
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Adaptive Phage Therapeutics, Inc. 708 Quince Orchard Road, Suite 205 Gaithersburg MD United States

Business Names
Business Name
Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics, LLC.
BiomX Ltd.
CHAC U
PHGE
PHGE U

General Information
Number of Employees: 58 (As of 12/31/2023)
Outstanding Shares: 55,220,077 (As of 3/28/2024)
Shareholders: 75
Stock Exchange: ASE
Fax Number: (800) 253-5177


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024